1. Home
  2. NAMS vs HAFN Comparison

NAMS vs HAFN Comparison

Compare NAMS & HAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • HAFN
  • Stock Information
  • Founded
  • NAMS 2019
  • HAFN 2012
  • Country
  • NAMS Netherlands
  • HAFN Singapore
  • Employees
  • NAMS N/A
  • HAFN N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • HAFN
  • Sector
  • NAMS Health Care
  • HAFN
  • Exchange
  • NAMS Nasdaq
  • HAFN Nasdaq
  • Market Cap
  • NAMS 2.5B
  • HAFN 2.7B
  • IPO Year
  • NAMS N/A
  • HAFN N/A
  • Fundamental
  • Price
  • NAMS $17.96
  • HAFN $5.52
  • Analyst Decision
  • NAMS Strong Buy
  • HAFN Strong Buy
  • Analyst Count
  • NAMS 8
  • HAFN 1
  • Target Price
  • NAMS $42.88
  • HAFN $6.50
  • AVG Volume (30 Days)
  • NAMS 893.6K
  • HAFN 1.5M
  • Earning Date
  • NAMS 08-06-2025
  • HAFN 05-15-2025
  • Dividend Yield
  • NAMS N/A
  • HAFN 16.57%
  • EPS Growth
  • NAMS N/A
  • HAFN N/A
  • EPS
  • NAMS N/A
  • HAFN 1.20
  • Revenue
  • NAMS $47,140,000.00
  • HAFN $2,631,664,000.00
  • Revenue This Year
  • NAMS N/A
  • HAFN N/A
  • Revenue Next Year
  • NAMS N/A
  • HAFN $1.88
  • P/E Ratio
  • NAMS N/A
  • HAFN $4.59
  • Revenue Growth
  • NAMS 586.97
  • HAFN N/A
  • 52 Week Low
  • NAMS $14.06
  • HAFN $3.61
  • 52 Week High
  • NAMS $27.29
  • HAFN $8.44
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 42.30
  • HAFN N/A
  • Support Level
  • NAMS $20.06
  • HAFN N/A
  • Resistance Level
  • NAMS $21.91
  • HAFN N/A
  • Average True Range (ATR)
  • NAMS 1.41
  • HAFN 0.00
  • MACD
  • NAMS -0.20
  • HAFN 0.00
  • Stochastic Oscillator
  • NAMS 4.45
  • HAFN 0.00

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About HAFN Hafnia Limited Common Shares

Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.

Share on Social Networks: